RDInvesting Provides Investors with Free In-Depth Equity Reports on AVHI, RKUS, VIPS and VNDA
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
AV Homes Inc. (NASDAQ: AVHI) shares surged 20.56 percent to close at $17.53 a share Wednesday. The stock traded between $15.00 and $17.99 on volume of 272,652 shares traded. The company announced that global private investment firm TPG has agreed to make a $135 million investment in the Company at a price of $14.65 per share.
Find out more about AV Homes including full access to the free equity report at:
www.RDInvesting.com/AVHI
Ruckus Wireless Inc. (NYSE: RKUS) shares spiked 5.52 percent to close at $12.04 a share Wednesday. The stock traded in between $11.36 and $12.24 on volume of 2.39 million shares traded. The company has recently been named one of the Bay Area News Group's (BANG) Top Workplaces for 2013. Shares of Ruckus Wireless have fallen approximately 46.5 percent year-to-date.
Find out more about Ruckus Wireless including full access to the free equity report at:
www.RDInvesting.com/RKUS
Vipshop Holdings Ltd. (NYSE: VIPS) shares declined 12.09 percent to close at $29.00 a share Wednesday. The stock traded between $28.99 and $32.49 on volume of 1.14 million shares traded. On May 30th, Analysts at Zacks upgraded the company’s rating to “outperform” from “neutral”. Shares of Vipshop have gained approximately 62.5 percent year-to-date.
Find out more about Vipshop including full access to the free equity report at:
www.RDInvesting.com/VIPS
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares declined 22.07 percent to close at $8.51 a share Wednesday. The stock traded in between $8.20 and $9.98 on volume of 8.62 million shares traded. The company has recently submitted a New Drug Application to the FDA for tasimelteon for the treatment of Non-24-Hour Disorder in the totally blind. Shares of Vanda Pharmaceuticals have gained approximately 130 percent year-to-date.
Find out more about Vanda Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/VNDA
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
info@rdinvesting.com